The global market for the Afluria influenza vaccine is gaining momentum as seasonal flu outbreaks intensify and the world’s elderly population swells—two forces that are reshaping public health priorities and creating new demand for immunization. A fresh report from The Business Research Company breaks down what’s driving this shift and where the opportunities lie through 2035.
The Business Research Company’s Afluria Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
The Afluria vaccine market occupies a critical space within the broader influenza prevention landscape, influenced by ongoing public health campaigns and shifting demographic patterns. Understanding the forces that are fueling its expansion—and the regional variations at play—offers a clearer view of what the next decade holds for this segment of the vaccine industry.
Also worth a look: TrussiAI plugs five roof-measurement tools directly into its contractor operating system and Get Simple Box Salem brings its award-winning containers to Albany home show for the first time.
Afluria Market Size and Growth Outlook
Historically, the Afluria market has grown thanks to recurring seasonal flu outbreaks and the rollout of public vaccination policies. Hospital-based immunization efforts and a rise in infection-driven hospital admissions have also contributed. Looking ahead, the market is projected to expand further as awareness of preventive healthcare increases, vaccination coverage goals widen, and retail pharmacy immunization services become more common. Better cold chain logistics and a growing elderly population are adding to that momentum. Key trends likely to shape the market include stronger demand for seasonal flu shots, expanded immunization programs for both children and adults, a heightened focus on preventive health measures, more aggressive government vaccination campaigns, and improved vaccine distribution networks.
Download a free sample of the afluria market report:
https://thebusinessresearchcompany.com/sample_request?id=13667582&type=smp&name=Afluria%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Understanding Afluria and Its Use
Afluria is an inactivated influenza vaccine designed to protect against specific flu virus strains. Approved for anyone aged six months and older, it is delivered by injection. The vaccine prompts the immune system to produce antibodies, offering protection against seasonal flu outbreaks. Annual vaccination is recommended to maintain effective immunity during flu season.
The Increasing Impact of Influenza on Market Growth
A key factor driving the Afluria market is the rising prevalence of influenza itself. This contagious respiratory illness, caused by influenza viruses, can produce symptoms ranging from fever and cough to sore throat, body aches, and fatigue—sometimes leading to severe outcomes. The increase in flu cases is tied to greater public awareness, evolving viral strains due to mutations, and growing demand for vaccination, particularly among vulnerable groups like older adults. For context, a November 2024 report from the UK Health Security Agency showed that influenza positivity climbed to 2.3% in week 41, up from 2%, with the highest infection rate of 5.1% recorded among children aged 5 to 14. Those numbers underscore the mounting need for vaccines such as Afluria to curb outbreaks and reduce complications.
View the full afluria market report:
https://thebusinessresearchcompany.com/report/afluria-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
The Role of the Aging Population in Market Expansion
Another major driver of the Afluria market is the growing geriatric population—those aged 65 and above. This demographic faces unique health risks and is especially vulnerable to severe outcomes from influenza. As life expectancy rises and fertility rates decline, the elderly population continues to expand, boosting demand for effective vaccines. According to data from the UK House of Commons Library published in July 2024, approximately 12.7 million people aged 65 and older lived in the UK in 2022, representing 19% of the population. That number is projected to reach 22.1 million by 2072, or 27% of the population. Such demographic trends highlight why protecting older adults with vaccines like Afluria is essential to reducing flu-related health risks.
Regional Leadership and Emerging Growth Areas in the Afluria Market
North America held the largest share of the Afluria market in 2025, reflecting its strong healthcare infrastructure and robust vaccination programs. Meanwhile, the Asia-Pacific region is expected to see the fastest growth over the forecast period. The Afluria market report delivers detailed insights across key regions—including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa—offering a comprehensive view of global market trends and opportunities.
New additions to our 2026 reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As flu seasons grow more unpredictable and the global population ages, the demand for reliable vaccines like Afluria will only intensify. Policymakers and healthcare investors should take note: the intersection of demographic shifts and rising infection rates is reshaping the influenza prevention market in ways that will have lasting implications for public health strategies and commercial opportunities alike.
